Small-molecule A485 mobilizes white blood cells on demand

New study reveals a small molecule that can selectively mobilize white blood cells, offering potential treatments for diseases with abnormal leukocyte counts.

Risk Adjusted Net Present Value: What is the current valuation of Roivant Sciences’s Brepocitinib tosylate

The revenue for Brepocitinib tosylate is expected to reach an annual total of $256 mn by 2035 in the US based off GlobalData’s Expiry Model.

May 16, 2024

UTHealth project aims to improve clinical trials for underserved people with neurological conditions

In an effort to close the gap in neurological outcomes for underserved populations, a UTHealth Houston project funded with $2.9 million from the National Institutes

January 11, 2025

Bayer inks deal to commercialize Mahana’s prescription digital therapeutics

Dive Brief: Bayer has formed a multi-million-dollar distribution and marketing partnership with the digital therapeutic developer Mahana Therapeutics. San Francisco-based Mahana received de novo clearance

August 23, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.